Skip to content

ROPI Study : Ropivacaine Interest in Postsurgical Pain After Mastectomy

ROPI Study: Evaluation of the Interest of Ropivacaine Streaming in Postoperative Pain After Mastectomy.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01855529
Acronym
ROPI
Enrollment
150
Registered
2013-05-16
Start date
2013-04-30
Completion date
2016-08-31
Last updated
2017-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain After Mastectomy

Keywords

ropivacaine, pain, mastectomy

Brief summary

After surgery for breast cancer, the prevalence of chronic pain is estimated between 20 and 68%. They begin after surgery and may persist until more than 6 months. They respond poorly to opioid analgesics impair the quality of life. Among the different postoperative analgesic techniques used, the use of a local anesthetic infiltration continues catheter has advantages including improving the quality of analgesia, with a significant decrease in average of VAS (scale visual Analogue), a decrease in morphine consumption, improving the quality of life of patients. Our study aims to evaluate the effectiveness of a continuous local anesthetic infiltration in the control of postoperative pain after mastectomy.

Interventions

DRUGRopivacaine in one arm and placebo (NaCl) in the other arm

Sponsors

Centre Jean Perrin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age\> 18 years * ASA I-II, WHO 0-1 * mastectomy alone, mastectomy + GGS + mastectomy CA * No previous history of chronic pain requiring regular intake of analgesics or long-term * Failure to take opioids within 30 days before surgery

Exclusion criteria

* Long-term treatment analgesic or taking opioids within 30 days before surgery * Concurrent treatment with a drug test, participation in another therapeutic clinical trial within \<30 days * proven allergy to local anesthetics of the amide * Skin Inflammation * Sepsis local * Kidney failure, liver failure, severe or poorly controlled diabetes * Inability to respond to the assessment of pain using a visual analogue scale (VAS) or a numerical scale (FR). * mastectomy with immediate breast reconstruction

Design outcomes

Primary

MeasureTime frame
Daily consumption of morphine during the first 48 postoperative hours.during the first 48 postoperative hours

Secondary

MeasureTime frame
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: • The intensity of pain, VAS or ENDuring the first 48 h after surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: • The site of painduring the first 48h after the surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: A potential analgesics administeredduring the first 48h after the surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: Constant: pulse, blood pressure, tympanic temperature, respiratory rate, sedation (0: awake, 1: sleepy, 2 comatose).during 48h after the surgery
Determination of Ropivacaine plasma (analytical blank: T0)T0, the day of surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: Possible side effects of ropivacaine expected the most common: nausea, vomiting, headache, dizziness, paresthesias.during 48 hours after the surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: Condition of dressing • On any abnormality at the site of administration: local redness, pain, skin warmth, pruritus.during the 48h after the surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: Determination of Ropivacaine plasma at T0+ 24 h, T0+48hduring 48h after the surgery
Assessment every 4 hours by the IDE that will support the patient during the first 48 hours, then every analgesic taken: Possible side effects The most common expected morphine: nausea, vomiting, pruritus, acute urine retention.during the 48h after the surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026